-$0.09 EPS Expected for Viking Therapeutics Inc (VKTX) This Quarter

Analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to post earnings of ($0.09) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Viking Therapeutics’ earnings, with estimates ranging from ($0.12) to ($0.07). Viking Therapeutics posted earnings of ($0.10) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 10%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, May 8th.

According to Zacks, analysts expect that Viking Therapeutics will report full year earnings of ($0.47) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.34). For the next financial year, analysts anticipate that the company will post earnings of ($0.62) per share, with EPS estimates ranging from ($0.92) to ($0.43). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03.

VKTX has been the subject of a number of recent analyst reports. Leerink Swann upgraded Viking Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.86 target price for the company in a report on Friday. Raymond James decreased their price objective on Viking Therapeutics from $43.00 to $40.00 and set a “strong-buy” rating for the company in a report on Thursday, March 14th. Svb Leerink raised Viking Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $10.00 to $21.00 in a research note on Friday. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a research report on Friday. Finally, B. Riley began coverage on Viking Therapeutics in a research report on Tuesday, December 11th. They set a “buy” rating and a $16.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $22.54.

VKTX traded up $1.43 during midday trading on Monday, hitting $9.94. The stock had a trading volume of 14,925,923 shares, compared to its average volume of 3,298,008. Viking Therapeutics has a 1 year low of $3.69 and a 1 year high of $24.00.

Large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Viking Therapeutics in the fourth quarter worth about $30,000. Lindbrook Capital LLC purchased a new position in Viking Therapeutics in the fourth quarter worth about $36,000. Quantbot Technologies LP purchased a new position in Viking Therapeutics in the third quarter worth about $109,000. Great West Life Assurance Co. Can purchased a new position in Viking Therapeutics in the fourth quarter worth about $53,000. Finally, Meeder Asset Management Inc. boosted its position in Viking Therapeutics by 63.5% in the fourth quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 2,839 shares during the last quarter. 65.31% of the stock is currently owned by institutional investors and hedge funds.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Read More: Dividend Aristocrat Index

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.